Specific to our test case at hand is that current cIMPACT guidelines dictate that documentation of TP53 mutation and concurrent ATRX mutation within an IDH‐mutant tumor excludes the diagnosis of oligodendroglioma. This evidence concerns the gene TP53 and neoplasm.